You are here
The Pricing Framework for Australian Public Hospital Services 2020-21 (the Pricing Framework) is the key strategic document underpinning the National Efficient Price (NEP) and National Efficient Cost (NEC) Determinations for the financial year 2020-21.
IHPA has issued the Pricing Framework prior to releasing the NEP20 and NEC20 Determinations, which will be publicly available in March 2020, with the intention of providing an additional layer of transparency and accountability.
There is a growing discussion in Australia and internationally about the need to increase focus on delivering value-based health care with a focus on patient outcomes and experience.
IHPA’s Pricing Guidelines and the National Health Reform Agreement include provisions for IHPA to consider the impact on its work of evidence‑based, effective new technologies and innovations in models of health care.
The Clinical Coding Practice Framework aims to support national consistency in clinical coding practice, by providing guidance in defining and promoting good practices for those involved in the clinical coding process.
It was developed by the Health Information Management Association of Australia in conjunction with the Clinical Coders’ Society of Australia, and incorporated feedback from public consultation.
A jurisdiction may request IHPA to consider any legitimate and unavoidable costs in the delivery of public hospital services. The purpose of this Framework is to assist jurisdictions in making submissions to IHPA on this issue, to layout the process which IHPA will follow in assessing submissions, and the process to determine adjustments to the NEP.
This Framework outlines the processes to investigate cross-border and cost-shifting disputes following a request by a health minister to ensure the timely, equitable and transparent management of these disputes.
The Impact of New Health Technology Framework (the Framework) outlines the process by which IHPA, via its Clinical Advisory Committee (CAC), will monitor and review the impact of new health technologies on the existing classifications in order to accurately account for them in the pricing of public hospital services.
In consultation with the CAC, IHPA will:
The ICD-10-AM/ACHI/ACS classification system is comprised of the following classifications:
The Independent Hospital Pricing Authority (IHPA) is currently developing a new classification for non-admitted care - the Australian Non-Admitted Care Classification (ANACC) - in response to the recommendations of public consultations in 2013 and 2014 on non-admitted care classification.
This report presents the results of phase one of the project to develop Australian Refined Diagnosis Related Groups (AR-DRG)1 Version (V) 8.0. This phase focuses on the case complexity component of the classification that has not been reviewed for many years
The non-admitted study was comprehensive across a range of settings (e.g. outpatients, community and satellite clinics). Similarly all service streams were included regardless of funding source. This ensured that all services were accounted for and costed appropriately providing an accurate cost of delivering multiple services across multiple settings (e.g. overhead costs are apportioned across all patients).
The Pricing Framework for Australian Public Hospital Services 2014-2015 builds on the two previous Pricing Frameworks (2012-2013 Pricing Framework and 2013-2014 Pricing Framework). For simplicity, where IHPA reaffirmed a previous principle, the supporting argument was not restated in this paper.
The costing study on home delivered dialysis was undertaken in 2014. The purpose of the study was to collate and compare the range of costing studies and economic evaluations that have been carried out on these services over the past decade.
The report identifies two key studies - NSW Dialysis Costing Study, conducted in 2008, and Queensland Health Renal Replacement Therapy Costing Study, conducted in 2008 - which are useful in estimating the current costs of home-based dialysis.
PwC and its sub-contractor The Independent Hospital Pricing Authority (IHPA) engaged PwC and its sub-contractor SyRis Consulting to undertake a review and costing study of Australian radiotherapy services. The study was commissioned to determine the reliability of radiotherapy cost data due to its role in the development of associated price weights in both admitted and non-admitted settings.
*The documents on this page may not meet accessibility (WCAG 2.0) requirements. If you need help please contact us using the enquiries.ihpa [at] ihpa.gov.au (IHPA enquiries).